Correlation Between Spyre Therapeutics and Comstock Holding

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and Comstock Holding at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and Comstock Holding into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Spyre Therapeutics and Comstock Holding Companies, you can compare the effects of market volatilities on Spyre Therapeutics and Comstock Holding and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of Comstock Holding. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and Comstock Holding.

Diversification Opportunities for Spyre Therapeutics and Comstock Holding

0.39
  Correlation Coefficient

Weak diversification

The 3 months correlation between Spyre and Comstock is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and Comstock Holding Companies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Comstock Holding Com and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with Comstock Holding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Comstock Holding Com has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and Comstock Holding go up and down completely randomly.

Pair Corralation between Spyre Therapeutics and Comstock Holding

Given the investment horizon of 90 days Spyre Therapeutics is expected to under-perform the Comstock Holding. But the stock apears to be less risky and, when comparing its historical volatility, Spyre Therapeutics is 1.26 times less risky than Comstock Holding. The stock trades about -0.05 of its potential returns per unit of risk. The Comstock Holding Companies is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  860.00  in Comstock Holding Companies on September 14, 2024 and sell it today you would lose (20.00) from holding Comstock Holding Companies or give up 2.33% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Spyre Therapeutics  vs.  Comstock Holding Companies

 Performance 
       Timeline  
Spyre Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Comstock Holding Com 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Comstock Holding Companies are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong fundamental indicators, Comstock Holding is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

Spyre Therapeutics and Comstock Holding Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Spyre Therapeutics and Comstock Holding

The main advantage of trading using opposite Spyre Therapeutics and Comstock Holding positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, Comstock Holding can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Comstock Holding will offset losses from the drop in Comstock Holding's long position.
The idea behind Spyre Therapeutics and Comstock Holding Companies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance